The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay

Bergwerk, 2021, Covid-19 Breakthrough Infections in Vaccinated Health Care Workers, N Engl J Med, 10.1056/NEJMoa2109072 Danese, 2021, Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA, J Med Biochem, 40, 1, 10.5937/jomb0-31475 Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, Humphries HE, Jepson B, Kelly EJ, Plested E, Shoemaker K, Thomas KM, Vekemans J, Villafana TL, Lambe T, Pollard AJ, Voysey M, the Oxford COVID Vaccine Trial Group. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. MedRxiv 2021.06.21.21258528; doi: https://doi.org/10.1101/2021.06.21.21258528. Lippi, 2021, Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?, Diagnostics (Basel), 11, 941, 10.3390/diagnostics11060941 Perkmann, 2021, Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222, Int J Infect Dis, 10.1016/j.ijid.2021.07.063